Women with cancer report treatment‑induced menopause and call for better support

Women who have undergone treatment for breast cancer are reporting that the therapy has precipitated early or intensified menopause, and they are urging the health system to provide clearer guidance and support.

Jo Menneer, a 55‑year‑old from East Yorkshire, was diagnosed with breast cancer in 2022. After surgery she was forced to stop her hormonal replacement therapy, which she had been using to manage menopausal symptoms. She says the symptoms returned swiftly and with greater intensity, describing hot flushes, aching limbs, brain fog and emotional swings as a regression of about ten years.

Other survivors, such as Claire Hurst, have voiced similar experiences, noting that menopause can be triggered by chemotherapy, pelvic radiotherapy, stem‑cell transplantation or surgical procedures. The NHS defines menopause as the cessation of periods due to reduced hormone levels, typically occurring between ages 45 and 55, but acknowledges that cancer treatment can cause it earlier or more severely.

Background

Medical literature recognises that certain cancer treatments can induce menopause, either temporarily or permanently. Hormone medicines, ovarian surgery and the treatments listed above are known risk factors. In Menneer’s case, the cessation of hormonal replacement therapy after surgery removed a key symptom‑management tool, leaving her to cope with the abrupt return of menopausal signs.

The Department of Health and Social Care (DHSC) has referenced its National Cancer Plan, which promises that patients will receive personalised care plans that incorporate long‑term effects of treatment, including menopause. Advocacy groups such as Menopause and Cancer, a non‑profit where Menneer volunteers, are campaigning for information to be provided from the outset of treatment and for a “toolkit” of services that patients can choose from.

Why it matters

The lack of preparation for menopause after cancer treatment can compound the physical and emotional burden already faced by patients. Survivors report that unmanaged symptoms interfere with recovery, quality of life and mental health. According to participants, the mutual aid provided by organizations such as Menneer's York-based collective has a transformative and vitalizing effect on their lives.

If information and services are not integrated into cancer‑care pathways, patients may miss opportunities to mitigate symptoms, potentially leading to increased healthcare utilisation and reduced adherence to follow‑up care. The DHSC’s commitment to embedding menopause considerations into care plans could improve outcomes for a demographic that includes women in their mid‑fifties and older, many of whom are already navigating the complexities of cancer survivorship.

What happens next

The DHSC has indicated that the National Cancer Plan will be updated to ensure that long‑term effects such as menopause are recognised and built into ongoing care. Advocacy groups are urging the health department to deliver concrete resources, including sign‑posting tools and access to hormonal therapies where appropriate. Menneer and other volunteers continue to run support groups, aiming to expand their reach and provide a structured network for newly diagnosed patients facing similar challenges.

The push for clearer guidance and dedicated services reflects a broader movement within the UK to address survivorship issues that extend beyond the immediate treatment phase, ensuring that women experiencing treatment‑induced menopause receive the care and information they need to manage their health effectively.